3A Comparison between R-THP-COP and R-CHOP Regimens for the Treatment of Diffuse Large B-cell Lymphoma in Old Patients : A Single-institution Analysis

• Material Type: 文書・図像類
• Title: 3A Comparison between R-THP-COP and R-CHOP Regimens for the Treatment of Diffuse Large B-cell Lymphoma in Old Patients : A Single-institution Analysis
• Author/Editor: Araie, Hiroaki; Sakamaki, Ippei; Matsuda, Yasufumi; Tai, Katsunori; Ikegaya, Satoshi; Itoh, Kazuhiro; Kishi, Shinji; Oiwa, Kana; Okura, Miyuki; Tasaki, Toshiki; Hosono, Naoko; Ueda, Takanori; Yamauchi, Takahiro
• Author Heading: Araie, Hiroaki; Sakamaki, Ippei; Matsuda, Yasufumi; Tai, Katsunori; Ikegaya, Satoshi; Itoh, Kazuhiro; Kishi, Shinji; Oiwa, Kana; Okura, Miyuki; Tasaki, Toshiki; Hosono, Naoko; Ueda, Takanori; Yamauchi, Takahiro
• Publication, Distribution, etc.: The Japaneses Society of Internal Medicine
• Publication Date: 2017-09-15
• Publication Date (W3CDTF): 2017-09-15
• Periodical title: Internal Medicine
• No. or year of volume/issue: 56 18
• Volume: 56
• Issue: 18
• Pages: 2407-2413
• Text Language Code: eng
• Subject Heading: diffuse large B cell lymphoma; R-CHOP; R-THP-COP; pirarubicin; old patients
• Target Audience: 一般
• Note (General): Objective We retrospectively compared the clinical efficacy and toxicity of rituximab (R)-THP-COP (pirarubicin, cyclophosphamide, vincristine, and prednisolone) with that of R-CHOP (rituximab, adriamicin, cyclophosphamide, vincristine, and prednisolone) in previously untreated old patients with diffuse large B-cell lymphoma (DLBCL).Patients and Methods Patients admitted to our institution between 2004 and 2013 were examined. The patients received either R(375 mg/m2, day 1)-THP-COP (pirarubicin 50 mg/m2 day 1, cyclophosphamide 750 mg/m2 day 1, vincristine 1.4 mg/m2 day 1, and prednisolone 100 mg day 1-5) or R-CHOP (adriamicin 50 mg/m2 day 1, cyclophosphamide 750 mg/m2 day 1, vincristine 1.4 mg/m2 day 1, and prednisolone 100 mg day 1-5). The doses of chemotherapeutic agents were adjusted depending on the patient's age and associated complications. The treatment was performed for 6 to 8 cycles.Results Among 74 patients with DLBCL (median 76, range 65-90 years; male 39, female 35), 29 received R-THP-COP, while 45 received R-CHOP. The overall response rates were 94.6% (complete response 86.4%, partial response 8.1%). The 2-year overall and progression-free survival rates were 77.6% and 68.5% for the R-THP-COP regimen and 79.2% and 78.9% for R-CHOP, respectively. No significant differences were found between these two regimens regarding the clinical efficacies. The most frequent adverse event was neutropenia (72.4% for the R-THP-COP regimen, 88.9% for the R-CHOP regimen). The cardiac function as evaluated by ejection fraction values was not impaired in either regimen.Conclusion R-THP-COP was effective and safe as an alternative to R-CHOP.
• Access Restrictions: 限定公開
• Rights (production): Copyright〓 2017 by The Japanese Society of Internal Medicine
• Related Material (DOI): 10.2169/internalmedicine.8291-16
• Data Provider (Database): 国立情報学研究所 : 学術機関リポジトリデータベース（IRDB）（機関リポジトリ）; https://irdb.nii.ac.jp
• Original Data Provider (Database): 福井大学 : 福井大学学術機関リポジトリ